News & Events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure to begin clinical development of novel dual arginase inhibitor OATD-02 for the treatment of cancer after gaining permission to conduct first clinical trial in Poland
28 November 2022
Molecure Third Quarter 2022 Pipeline Highlights and Financial Results
31 October 2022
Molecure reports continued pipeline momentum for 6 months ended 30th June 2022
29 September 2022
Molecure announces filing of Clinical Trial Application with Polish regulator for OATD-02, a novel dual arginase inhibitor being developed for the treatment of cancer
11 August 2022
Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01
23 June 2022